List of works - Camilla Evangelisti

Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia.

scientific article published on 28 September 2010

Advances in targeting signal transduction pathways

scientific article

Advances in understanding the acute lymphoblastic leukemia bone marrow microenvironment: From biology to therapeutic targeting

scientific article published on September 2015

Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy

scientific article published on 21 February 2008

Autophagy in acute leukemias: a double-edged sword with important therapeutic implications

scientific article

Current treatment strategies for inhibiting mTOR in cancer

scientific article

Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia.

scientific article published on 22 May 2012

DGKζ is degraded through the cytoplasmic ubiquitin-proteasome system under excitotoxic conditions, which causes neuronal apoptosis because of aberrant cell cycle reentry.

scientific article published on 6 April 2012

GSK-3β: a key regulator of breast cancer drug resistance

scientific article published on 04 February 2014

Identification of a functional nuclear export sequence in diacylglycerol kinase-zeta.

scientific article published on 29 January 2010

Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway

scientific article published on 24 October 2016

Increased NGAL (Lnc2) expression after chemotherapeutic drug treatment.

scientific article

Modulation of TGFbeta 2 levels by lamin A in U2-OS osteoblast-like cells: understanding the osteolytic process triggered by altered lamins

scientific article

Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response

scientific article published on September 2012

Nuclear diacylglycerol kinase-zeta is a negative regulator of cell cycle progression in C2C12 mouse myoblasts

scientific article published on 8 May 2007

Nuclear inositol lipid metabolism: more than just second messenger generation?

scientific article

Nuclear phosphoinositides and their roles in cell biology and disease

scientific article published on 14 September 2011

PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines

scientific article

PI3K/AKT/mTORC1 and MEK/ERK signaling in T-cell acute lymphoblastic leukemia: new options for targeted therapy

scientific article published on 01 January 2012

Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia

scientific article

Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia.

scientific article

Potential therapeutic effects of the MTOR inhibitors for preventing ageing and progeria-related disorders

scientific article

Preclinical testing of the Akt inhibitor triciribine in T-cell acute lymphoblastic leukemia.

scientific article published on March 2011

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance

scientific article

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health

scientific article published on March 2011

Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging

scientific article

Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance

scientific article

Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy.

scientific article published on 15 April 2011

Subnuclear localization and differentiation-dependent increased expression of DGK-zeta in C2C12 mouse myoblasts.

scientific article

Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB.

scientific article published on 22 November 2015

TIS21/BTG2/PC3 and cyclin D1 are key determinants of nuclear diacylglycerol kinase-zeta-dependent cell cycle arrest

scientific article published on 20 January 2009

Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia.

scientific article published on 18 February 2011

Targeting Wnt/β-catenin and PI3K/Akt/mTOR pathways in T-cell acute lymphoblastic leukemia

scientific article published on 06 January 2020

Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia

scientific article published on 11 June 2013

Targeting signaling pathways in T-cell acute lymphoblastic leukemia initiating cells

scientific article published on 30 April 2014

Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia

scientific article published in September 2009

Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance.

scientific article published on 26 March 2007

Targeting the cancer initiating cell: the ultimate target for cancer therapy.

scientific article published on January 2012

Targeting the liver kinase B1/AMP-activated protein kinase pathway as a therapeutic strategy for hematological malignancies

scientific article published on 12 June 2012

Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway

scientific article

The Cutting Edge: The Role of mTOR Signaling in Laminopathies

scientific article published on 15 February 2019

The Unfolded Protein Response: A Novel Therapeutic Target in Acute Leukemias

scientific article published on 01 February 2020

The emerging multiple roles of nuclear Akt

scientific article

The emerging role of the phosphatidylinositol 3-kinase/ akt/mammalian target of rapamycin signaling network in cancer stem cell biology

scientific article published on 18 August 2010

The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in normal myelopoiesis and leukemogenesis.

scientific article published on 23 April 2010

The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion

scientific article published on 15 March 2007

The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients.

scientific article

Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update

scientific article published on 26 June 2018

Therapeutic potential of targeting mTOR in T-cell acute lymphoblastic leukemia (review).

scientific article published on 26 June 2014

Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia

scientific article

Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment.

scientific article

List of works by Camilla Evangelisti

Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia.

Advances in targeting signal transduction pathways

Advances in understanding the acute lymphoblastic leukemia bone marrow microenvironment: From biology to therapeutic targeting

Alteration of Akt activity increases chemotherapeutic drug and hormonal resistance in breast cancer yet confers an achilles heel by sensitization to targeted therapy

Autophagy in acute leukemias: a double-edged sword with important therapeutic implications

Current treatment strategies for inhibiting mTOR in cancer

Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia.

DGKζ is degraded through the cytoplasmic ubiquitin-proteasome system under excitotoxic conditions, which causes neuronal apoptosis because of aberrant cell cycle reentry.

GSK-3β: a key regulator of breast cancer drug resistance

Identification of a functional nuclear export sequence in diacylglycerol kinase-zeta.

Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway

Increased NGAL (Lnc2) expression after chemotherapeutic drug treatment.

Modulation of TGFbeta 2 levels by lamin A in U2-OS osteoblast-like cells: understanding the osteolytic process triggered by altered lamins

Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response

Nuclear diacylglycerol kinase-zeta is a negative regulator of cell cycle progression in C2C12 mouse myoblasts

Nuclear inositol lipid metabolism: more than just second messenger generation?

Nuclear phosphoinositides and their roles in cell biology and disease

PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines

PI3K/AKT/mTORC1 and MEK/ERK signaling in T-cell acute lymphoblastic leukemia: new options for targeted therapy

Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia

Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia.

Potential therapeutic effects of the MTOR inhibitors for preventing ageing and progeria-related disorders

Preclinical testing of the Akt inhibitor triciribine in T-cell acute lymphoblastic leukemia.

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health

Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging

Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance

Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy.

Subnuclear localization and differentiation-dependent increased expression of DGK-zeta in C2C12 mouse myoblasts.

Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB.

TIS21/BTG2/PC3 and cyclin D1 are key determinants of nuclear diacylglycerol kinase-zeta-dependent cell cycle arrest

Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia.

Targeting Wnt/β-catenin and PI3K/Akt/mTOR pathways in T-cell acute lymphoblastic leukemia

Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia

Targeting signaling pathways in T-cell acute lymphoblastic leukemia initiating cells

Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia

Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance.

Targeting the cancer initiating cell: the ultimate target for cancer therapy.

Targeting the liver kinase B1/AMP-activated protein kinase pathway as a therapeutic strategy for hematological malignancies

Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway

The Cutting Edge: The Role of mTOR Signaling in Laminopathies

The Unfolded Protein Response: A Novel Therapeutic Target in Acute Leukemias

The emerging multiple roles of nuclear Akt

The emerging role of the phosphatidylinositol 3-kinase/ akt/mammalian target of rapamycin signaling network in cancer stem cell biology

The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in normal myelopoiesis and leukemogenesis.

The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion

The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients.

Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update

Therapeutic potential of targeting mTOR in T-cell acute lymphoblastic leukemia (review).

Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia

Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment.